Form 4: Puma Biotechnology CFO Sells Shares Under 10b5-1 Plan

Puma Biotechnology's Chief Financial Officer, Maximo F. Nougues, sold 10,227 shares of common stock at an average price of $3.1517 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Maximo F. Nougues, the Chief Financial Officer of Puma Biotechnology, sold 10,227 shares of the company's common stock on January 2, 2025.
• The shares were sold at a weighted average price of $3.1517 per share.
• The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 14, 2020.
• The price range for the transactions was between $3.11 and $3.2101 per share.
• Following the transaction, Mr. Nougues directly owns 152,295 shares of Puma Biotechnology.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales.
• The reported transaction is consistent with typical insider trading disclosures.
• Similar filings are regularly made by executives at other publicly traded companies such as Amgen, Gilead, and Biogen.

Stakeholder Impact

• The stock sale by the CFO may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

Puma Biotechnology, PBYI, Maximo F. Nougues, Chief Financial Officer, stock sale, Form 4, 10b5-1 plan, insider trading